Standard BioTools Stock

Standard BioTools Net Tangible Assets

The Net Tangible Assets of Standard BioTools (LAB) as of Aug 10, 2026 is 424.29 M USD. In the previous year, Net Tangible Assets was 331.42 M USD — a change of 28.02% (higher).

Net Tangible Assets

424.29 MUSD

YoY

28.02%

Last updated:

Net Tangible Assets of Standard BioTools is 2026 424.29 M USD. Net Tangible Assets of Standard BioTools was 2025 331.42 M USD. It decreases by 28.02% higher compared to the previous year.
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Net Tangible Assets of Standard BioTools is 424.29 M USD in 2026.

Net Tangible Assets of Standard BioTools changed from 331.42 M USD to 424.29 M USD, representing a 28.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Standard BioTools

All Key Metrics — Standard BioTools